Transcranial Doppler Monitoring for Brain Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new methods to assess brain health after sudden brain injuries in children. It uses Transcranial Doppler, similar to an ultrasound for the brain, to evaluate blood flow and oxygen delivery. The study aims to find better ways to measure brain function after injuries like severe head trauma or stroke. Children who have experienced a sudden brain injury and are hospitalized with a special monitoring line in their artery are suitable candidates for this trial. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could enhance brain injury care for children.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these methods are safe for assessing cerebral autoregulation?
Research has shown that Transcranial Doppler (TCD) safely monitors brain activity. Studies have demonstrated its safe use in various situations, such as aiding doctors in deciding if a patient can go home early after a mild head injury. Another study confirmed that TCD is both practical and safe in medical procedures.
TCD is a non-invasive method for checking blood flow in the brain. It serves as a dependable and repeatable alternative to techniques like CT scans. Overall, TCD is easy for patients to tolerate, making it a promising choice for monitoring brain injuries.12345Why are researchers excited about this trial?
Transcranial Doppler Monitoring is unique because it offers a non-invasive way to assess and monitor brain injuries by measuring blood flow in the brain's blood vessels. Traditional methods like CT scans or MRIs provide static images, but Transcranial Doppler allows for real-time monitoring, giving doctors immediate feedback on how well the brain is being supplied with blood. Researchers are excited about this technique because it can potentially lead to quicker, more dynamic responses in treatment plans, ultimately improving patient outcomes by allowing for timely interventions.
What evidence suggests that these methods are effective for assessing cerebral autoregulation?
Research shows that Transcranial Doppler (TCD) is a useful tool for assessing brain health after an injury. Studies have found that TCD helps predict recovery outcomes for patients with head injuries. For instance, using TCD within 24 hours of a serious head injury can provide insights into the patient's condition six months later. One study found that TCD can detect early signs of brain problems in these patients. Overall, TCD has proven valuable in managing brain injuries by aiding in the prediction and monitoring of brain function. Participants in this trial will be monitored using TCD to evaluate its effectiveness in predicting and managing brain injury outcomes.46789
Who Is on the Research Team?
Darryl Miles
Principal Investigator
University of Texas Southwestern Medical Center
Are You a Good Fit for This Trial?
This trial is for children and teens (28 days to 18 years old) who have had a serious brain injury like trauma or stroke within the last day. They must be in the PICU at Children's Medical Center Dallas with an arterial line already placed for care, and some may also have ICP monitoring.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Acute Monitoring
Non-invasive monitoring of cerebral autoregulation using TCD and NIRS over the first 7-10 days post-injury
Follow-up
Participants are monitored for neurologic outcomes using GOSEP and PEDI-CAT at hospital discharge, 3, 6, and 12 months post-injury
What Are the Treatments Tested in This Trial?
Interventions
- Transcranial Doppler
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Southern Methodist University
Collaborator
The University of Texas at Arlington
Collaborator